Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Critical Steps for Long-Term Management of HBV: Focus on Monitoring and HBV Reactivation

Premiere Date: Monday, July 12, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, July 12, 2022
Note: Credit Is No Longer Available


Joseph K. Lim, MDJoseph K. Lim, MD 
Professor of Medicine
Director, Clinical Hepatology
Section of Digestive Diseases/Yale Liver Center
Yale University School of Medicine
New Haven, CT

Statement of Need

New targeted treatment and biologics have revolutionized immunosuppression for patients with cancer, autoimmune diseases, and anti-rejection agents, but are associated with HBV reactivation (HBVr) at various levels of risk. Additionally, HBVr occurs in patients with HBV-HCV coinfection receiving viral agents. Clinicians need to be aware of potential HBVr related to immunosuppressive therapies that are increasingly common across many specialties and should screen patients for HBV prior to initiation of treatment to reduce HBVr associated morbidity and mortality.

In this CME Outfitters BriefCase you meet Thomas, a 31-year-old man who immigrated from Nigeria as a child and has been diagnosed with CD20-positive B-cell non-Hodgkin's lymphoma. His case will be used to illustrate the importance of screening at-risk patients for HBV and routinely monitoring patients with HBV who are immunosuppressed every 6 months for disease progression, HCC, and HBV reactivation.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Routinely monitor patients with HBV every 6 months for disease progression, HCC, and HBV reactivation in patients who are immunosuppressed.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Describe ways to routinely monitor patients with HBV every 6 months for disease progression, HCC, and HBV reactivation in patients who are immunosuppressed.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: JA0007185-0000-21-119-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to PAs: PAs may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Lim reports that he receives research support from Allergan; Celgene Corporation; Eiger BioPharmaceuticals; GENFIT; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download